Merck reported a narrower-than-expected quarterly loss and raised its full-year outlook as the drugmaker battled past generic competition and a slump in its leading vaccine franchise. The ...

When it comes to meeting nutrition needs, Dr. Marion Nestle, one of the country’s foremost nutrition policy experts, said ...

Merck (MRK) is scheduled to report first-quarter earnings on April 30, during market hours, with analysts expecting a strong performance from Keytruda and Winrevair. Seeking Alpha analyst ALLKA ...

Merck narrows 2026 outlook, but analysts see revision as less compelling Investors focus on pipeline and efforts to reduce reliance on Keytruda Merck booked $3.62-per-share charge for Cidara buyout ...

Scientists are uncovering how the volume of food on your plate affects appetite and satiety—challenging the idea that cutting portions is the most effective strategy. For decades, weight loss has been ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...

Mukbang videos have become a lifeline for university-age women, whose content pays college fees, supports their families, and supplants traditional career paths. Stills taken from the social media ...

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales ...

Lunch plays a crucial role in fueling your afternoon energy, stabilizing blood sugar, and supporting overall health. While meal timing research often focuses on breakfast and dinner, the studies on ...

This nutritious, versatile snack can support digestive health, appetite control, and workout performance. Learn more about when to consume dates for each potential benefit.

British chef Mike Keen will ski across Greenland eating only fermented seal. Researchers will study how the Inuit diet shapes ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...